

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/G58F4926772EN.html>

Date: October 2018

Pages: 62

Price: US\$ 3,500.00 (Single User License)

ID: G58F4926772EN

Abstracts

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'Glucosylceramidase - Pipeline Review, H2 2018'; Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) pipeline Target constitutes close to 15 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Glucosylceramidase belong to the family of hydrolases that catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids. Deficiency in Beta-glucocerebrosidase enzymatic activity, results in accumulation of lipid glucocerebroside in tissue macrophages (Gaucher cells). Enzyme replacement therapy leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside.

The report 'Glucosylceramidase - Pipeline Review, H2 2018' outlays comprehensive information on the Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics development with respective active and dormant or discontinued projects.

Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 6 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Gaucher Disease, Parkinson's Disease, Gaucher Disease Type I, Gaucher Disease Type II, Amyotrophic Lateral Sclerosis and Gaucher Disease Type III.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45)

The report reviews Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics and enlists all their major and minor projects

The report assesses Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N

Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Overview

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N

Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N

Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N

Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Companies Involved in Therapeutics Development

AvroBio Inc

Biosidus SA

GT Gain Therapeutics SA

JCR Pharmaceuticals Co Ltd

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N

Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Drug Profiles

ADN-LYS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ambroxol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ambroxol hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVRRD-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Activate Glucocerebrosidase for Genetic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Glucosylceramidase for Gaucher Disease Type II - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiglucerase biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiglucerase biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LTI-291 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCGC-607 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pcgin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate GBA for Gaucher Disease - Drug Profile

Product Description

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Bet...

Mechanism Of Action

R&D Progress

Small Molecules to Activate GCase for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Glucocerebrosidase for Gaucher Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

taliglucerase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

taliglucerase alfa biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

velaglucerase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N
Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or
EC 3.2.1.45) - Dormant Products

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N
Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or
EC 3.2.1.45) - Discontinued Products

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N
Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or
EC 3.2.1.45) - Product Development Milestones

Featured News & Press Releases

Oct 01, 2018: AVROBIO receives no objection to clinical trial application from Health
Canada for AVR-RD-02 gene therapy for gaucher disease

Jul 17, 2018: Fetal gene therapy prevents fatal neurodegenerative disease

Mar 22, 2017: AVROBIO Expands Rare Disease Pipeline with Gene Therapy to Treat
Gaucher Disease

Dec 27, 2016: Protalix BioTherapeutics Receives Confirmation of Order for over \$24
Million of alfataliglycerase to Treat Gaucher Patients in Brazil

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Bet...

Dec 14, 2016: Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately \$24 Million of alfatriglicerol to Treat Gaucher Patients in Brazil

Nov 22, 2016: Alfatriglicerol Approved for Pediatric Indications in Brazil for the Treatment of Gaucher Disease in Children Four years and Older

Oct 25, 2016: Asthma research unexpectedly yields new treatment approach for inherited enzyme disease

Jul 12, 2016: Researchers make advance in possible treatments for Gaucher, Parkinson's diseases

Feb 12, 2015: Safety and Efficacy of ELELYSO (taliglucerase alfa) for Injection in Pediatric Patients with Type 1 Gaucher Disease in Long-term Outcome Study Presented at the WORLDSymposium 2015

Sep 02, 2014: Shire's VPRIV400 units/vial launched in Japan for the improvement of symptoms of Gaucher disease

Aug 28, 2014: Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease

Jul 04, 2014: Shire's VPRIV approved in Japan for the improvement of symptoms of Gaucher disease

Jul 01, 2014: Pfizer Receives Kosher Certification for Elelyso (taliglucerase alfa) for Injection, for the Treatment of Type 1 Gaucher Disease

Jun 27, 2014: Protalix Announces New Data on ELELYSO (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting

Jun 23, 2014: Protalix BioTherapeutics Announces New Data on ELELYSO (taliglucerase alfa) and Oral GCD to be Presented at the European Working Group on Gaucher Disease 2014 11th Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AvroBio Inc, H2 2018
Pipeline by Biosidus SA, H2 2018
Pipeline by GT Gain Therapeutics SA, H2 2018
Pipeline by JCR Pharmaceuticals Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Avrobio Inc

Biosidus SA

GT Gain Therapeutics SA

JCR Pharmaceuticals Co Ltd

I would like to order

Product name: Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/G58F4926772EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G58F4926772EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970